Background Acquired haemophilia A (AHA) is an autoimmune bleeding disorder with significant morbidity and mortality. Bleeding AHA patients with high titre inhibitors can be treated with either activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa). Given that both replacement therapies have inherent benefits and limitations, a cost-effectiveness analysis (CEA) was performed in this population to compare rFVIIa with aPCC.
Introduction
Acquired haemophilia A (AHA) is an acquired bleeding disorder with significant morbidity and mortality [1] [2] [3] . It is a rare autoimmune disorder affecting 1Á3-1Á5 cases per million annually, usually in the elderly population (median age between 64 and 78 years) [2, 4, 5]. The condition results from the spontaneous formation of autoantibodies against factor VIII [6] . Patients with AHA usually present with large haematomas, extensive ecchymoses or severe mucosal bleeding [4] . Many of the haemorrhages can be limb-or life-threatening [4, 7, 8] , and the mortality can be greater than 20% in high-risk patients [9] . For example, according to one study, 22% of patients died from haemorrhage or complications attributed directly to the disease [10] . Therapies include immunosuppression, bleeding control, eradication of the inhibitors and treatment of the underlying condition (if applicable). In bleeding patients with high titre inhibitors, bypassing medications, such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC), should be initiated promptly [2] . Both rFVIIa [11] and aPCC [12] are FDA-approved for the treatment of bleeding in patients with AHA [2] . However, each has its own advantages and disadvantages. For example, rFVIIa is a recombinant product, and thus, theoretically, there is less risk of transfusion-transmitted infections by both known and unknown agents compared to human plasma-derived products such as aPCC. On the other hand, due to the concurrent presence of other coagulation factors, some of which have long half-lives, aPCC may carry a higher risk of thrombosis if repeated doses are given over a long period of time. Given that AHA is a condition with high morbidity and mortality, and both rFVIIa and aPCC are currently FDA-approved for the treatment of haemorrhage in these patients, although both replacement therapies have inherent benefits and limitations, we developed an economic model to rigorously examine the cost-effectiveness of rFVIIa and aPCC in the treatment of bleeding in patients with AHA and high titres of anti-factor VIII antibody using actual institutional costs as well as clinical data on outcomes and complications from the literature.
Materials and methods

Patient population
The hypothetical patient cohort was modelled using the profiles of actual patients. An extensive literature search was performed to identify important clinical trials and observational studies with actual patients with AHA and bleeding in order to provide the estimates for the model parameters (Table 1) . AHA was diagnosed based on clinical bleeding and laboratory results showing the patient had a severe deficiency of factor VIII with the presence of a high inhibitor titre [>5 Bethesda units (BU)], and thus, required treatment with a bypassing agent, such as rFVIIa or aPCC [2].
Model structure
A Markov decision analytic model (Fig. 1 ) was developed using Microsoft Excel (Microsoft Corporation, Redmond, WA) to simulate a hypothetical cohort of adult patients admitted to the hospital with bleeding due to AHA. Specifically, these bleeding patients with AHA (with a high level of inhibitor >5 BU) were treated with either rFVIIa (represented by NovoSeven, Novo Nordisk, Plainsboro, NJ) or aPCC (represented by FEIBA, Shire, Lexington, MA). Regardless of the treatment, the model was developed such that the patients transitioned into four different health states: (1) continuous bleeding, (2) thrombosis, (3) stop bleeding and (4) death. All patients in the model were haemorrhaging initially, and thus, all of them entered the model at stage (1). Depending on the probability of the treatment efficacy and adverse events on each subsequent day, the patients either remained in state (1) or entered state (2), (3) or (4), which were modelled as absorbing states, which means that the patients did not transition into other states once they entered one of these three states. The assessment for transition between stages occurred at the beginning of the next day. For example, if the patient bled for 2 days [state (1)] and then experienced thrombosis [state (2)], then we assumed that it occurred at the beginning of day 3 {i.e. this patient would be included in the cost and utility [defined in the 'Model Outcomes'] section associated with state (1) for 2 days and state (2) for 3 days for a total of 5 days}. If the patient experienced a thrombotic event, we assumed that the event was severe so that no additional rFVIIa or aPCC was given.
Another assumption in the model was that there was no rebleeding event in this hypothetical cohort since the majority of rebleeding events occurred after 5 days, which was beyond the study period [7] .
A time horizon of 5 days was used for the analysis to estimate the immediate 5-day cost-effectiveness of rFVIIa vs. aPCC since the majority of patients reported in the literature achieved haemostasis within this time-period [7, 13, 14] . The cost-effectiveness analysis (CEA) was conducted from the payer perspective within the US, and we did not adjust for inflation with regard to costs and outcomes throughout the time horizon due to the short analysis period. Furthermore, given the rarity of the disease, the heterogeneity of the studies in the literature, and the uncertainty involving both the cost and effectiveness of the bypassing agents since there has been no comparative trial examining the superiority of either product [3], we chose to focus on the estimation of the joint density of cost and effectiveness differences and the quantification of uncertainty surrounding the incremental cost-effectiveness ratios (ICERs). Therefore, as recommended by Briggs and O'brien, a CEA analysis was performed instead of a cost-minimization analysis [15] . Additionally, we used a cost-effectiveness acceptability curve (CEAC) to evaluate the cost-effectiveness between these two treatment options over a range of values for the maximum acceptable ceiling ratio [16] .
Model outcomes
Similar to many conventional CEA studies, the outcomes of the model were estimates of healthcare resource utilization, which were (a) 5-day payer costs (in US dollars [USD] ; the cost outcome), (b) a health utility index as measured by quality-adjusted life days (QALDs) gained within 5 days (the effectiveness outcome) and (c) ICER, which was defined as ICER ¼ ðCost rFVIIa À Cost aPCC =Effectivenes rFVIIa À Effectivenes aPCC Þ using both cost and effectiveness outcomes [17, 18] . Typically, the ICER is the composite outcome used to determine whether an alternative method (rFVIIa) is cost-effective compared to a reference method (aPCC) for policy-making purposes. We chose aPCC to be the reference treatment because it was FDA-approved for the treatment of AHA approximately 20 years before rFVIIa received its approval. It was also the treatment of choice for AHA prior to the availability of rFVIIa as an alternative. We used a conventional cut-off ICER of < $50 000/QALY (equivalent to an ICER threshold of $684Á46 for our 5-day analysis) to determine whether an alternative method is cost-effective [17, 18] .
Clinical parameters
Clinical parameter estimates were derived from the best available medical literature based on the clinical trials and observational studies conducted on patients with AHA (Table 1) . Depending on the parameter, data from either a subgroup or all patients in the studies were used. Furthermore, if data were available from multiple studies, then these data were combined so that the average probability was input into the model, and the range of uncertainty around the estimate was accounted for in the sensitivity analyses. The probability at each decision node represented the daily probability of the four health states with the assumption that the daily rate of events was constant over the 5-day analysis. For example, in 9 days, Borg et al. [14] reported that there was one thrombosis in 26 patients treated with aPCC. Using the equations to convert from rate to probability suggested by Fleurence et al.
[19], the daily probability was calculated as
. Then, the 1-day probability of thrombosis of aPCC was estimated to be 1 À e À4Á36Ã10 À3 Ã1 or 4Á35 9 10 -3 .
Similar calculations were performed to approximate the other probability estimates (Tables 1) . The clinical response rates (i.e. bleeding stop) for AHA patients and congenital haemophilia A patients who developed factor VIII inhibitors when treated with aPCC or rFVIIa were similar [2, 7, 13]. Thus, since our model was based on the efficacy of each agent at 24 h, the data from Astermark et al.
[13] were used. Furthermore, the probability of a patient entering a continuous bleeding state was derived mathematically from the probabilities of the other states since these states were mutually exclusive. All clinical parameters were subjected to sensitivity analyses given the variability and heterogeneity of the patients and their health states in the medical literature.
Cost parameters
All costs were expressed in 2017 USD; those not expressed in 2017 USD were adjusted for medical care inflation (Table 1 ) [20] . Only direct institutional costs were included in the model. Similar to clinical parameters, all cost variables were subjected to sensitivity analyses. The costs for rFVIIa and aPCC at the University of Alabama at Birmingham Hospital (UABH), a large academic tertiary care centre in the Southeastern United States, were $2085Á34/mg and $1Á89/IU, respectively. Assuming the bleeding patient was 70 kg and that the patient received the maximum dose with each administration of the medication based on the available 'Prescribing Information' of each medication from the manufacturers, each day the patient would require 6 mg of rFVIIa (90 lg/kg 9 70 kg) every 2 h [11], which Fig. 1 Decision model -a Markov model for acquired haemophilia A patients with bleeding and high titre anti-factor VIII antibody (>5 BU) treated with either activated prothrombin complex concentrate (aPCC) or recombinant activated factor VII (rFVIIa). Regardless of the treatment (aPCC or rFVIIa), these patients underwent four different potential health states ((1) continuous bleeding, (2) thrombosis, (3) stop bleeding and (4) death) in a 5-day analysis using the data for clinical, utility and cost parameters in Table 1 . Of note, the dose of the medication (either aPCC or rFVIIa) was reduced to 50% the day before the patient stopped bleeding in the model. The utility for the last day of bleeding was also the average of the utility for continuous bleeding and the utility for stopped bleeding stage. [Colour figure can be viewed at wileyonlinelibrary.com] Since the assessment for transition between stage (1) and stage (3) (i.e. continuous bleeding and stop bleeding) occurred at the beginning of the next day in the model, we also assumed that the patient only required half of the medication dose (regardless if the patient was on rFVIIa or aPCC) on the day prior to the day the bleeding stopped. Furthermore, in the model, we assumed that the patients would remain in a non-intensive care unit (ICU) unless they experienced a thrombotic event. At that time, the patients would be transferred to the ICU and would not receive further rFVIIa or aPCC. Therefore, after adjustment for medical inflation [20] , the cost of a continuous bleeding state was the cost of a non-ICU day ($2219Á97) [21] , and the cost of a thrombotic state was the cost of an ICU day ($5172Á69) [22] . If the patient stopped bleeding, then there would be no more associated cost on the day that he or she stopped bleeding.
Utility estimates
The health utility index, which directly reflects the health status and health-related quality of life for each of the four health states described above, was derived from the best available evidence obtained from the literature and was subject to sensitivity analyses due to the variability and heterogeneity of patients and health states (Tables 1  and 2) . A utility score of 1 indicates a perfect health state while a score of 0 indicates death. Since there was no available utility index score study in bleeding patients with AHA and high titre antibody level, the utility estimates for continuous bleeding and thrombosis were based on the median utility values for gastrointestinal bleeding and deep vein thrombosis, respectively [23] . For the bleeding stop state, the value was derived from the average utility value of a nonbleeding state in haemophilia patients [24] . Since we assumed the medication dose was reduced to 50% on the day prior to the stopped bleeding day, the utility for that day was also the average of the utility for continuous bleeding and the utility for stopped bleeding stage. QALD estimates were calculated by multiplying the probabilities of each health state by the utility indices and adding the results per day over the 5-day time horizon. In contrast to the above one-way sensitivity analysis, which only examined the variation on one parameter at a time, PSA was also conducted using the Monte Carlo method of simulation to investigate the effects of multiple variations occurring at once in the model and to provide a single global analysis of uncertainty in decision [28] . We performed PSAs with 1000 simulations to estimate the influence of the range of input values (i.e. 95% confidence interval for each parameter estimate) on the ICER variable (Table 1) . Within the PSAs, we assumed the uncertainty in each variable followed the typical statistical distribution as conventionally done in health economic analysis. Specifically, the uncertainties in the transition probabilities from each health state and health state utilities were addressed using a b distribution. For cost, uncertainty was assessed using a c distribution.
Sensitivity analyses
Results
Model results
In the deterministic analysis (Table 3) , during the 5-day period for patients with AHA and bleeding who had a high titre anti-factor VIII antibody (>5 BU), the average total treatment cost of rFVIIa and aPCC was $13 635 and $1741, respectively (with an incremental difference of $11 894). At the same time, the average QALD gained for rFVIIa was slightly lower compared to aPCC (4Á08 vs. 4Á09). Overall, for the treatment of bleeding patients with AHA, aPCC prevailed over rFVIIa in both cost and effectiveness outcomes, and thus, it is the dominant strategy. 
Sensitivity analysis results
One-way sensitivity analysis indicated that the ICER was most sensitive to the range of possible estimates for the utility of stop bleeding, the probability of stop bleeding with rFVIIa and the probability of thrombosis with aPCC and rFVIIa (Fig. 2) . However, in all scenarios, either aPCC was cheaper and more effective (i.e. higher QALD gained) compared to rFVIIa, or the ICER value was greater than $684Á46/5-day QALD (which is equivalent to $50 000/ QALY), exceeding the threshold for declaring aPCC to be the preferred option for the 5-day analysis [17, 18] . Furthermore, the tested ranges for other variables did not result in a significant impact on the ICER variable; as such, these variables are not shown in Fig. 2 . In addition to the results of the one-way sensitivity analysis, the robustness of the model to all input variables was further confirmed by the PSA analysis (Table 4 and Fig. 3 ), which demonstrated that aPCC is a cost-effective treatment option when compared to rFVIIa for bleeding patients with AHA who have a high titre anti-factor VIII antibody (>5 BU). Additionally, CEAC showed the probability that the result remained valid over a range of values for the maximum acceptable ceiling ratio (Fig. 4) . Specifically, aPCC has more than 98% probability of being cost-effective up to $2737Á85/5 QALDs (which is equivalent to $200 000 per QALY).
Discussion
Acquired haemophilia A is a significant disease with potentially high morbidity and mortality without prompt initiation of treatment. If bleeding patients have high titres of anti-factor VIII antibody (>5 BU), then rFVIIa or aPCC should be promptly given. We developed a CEA model to rigorously examine these two treatment options in this population from a health economic perspective and have shown that aPCC is a cost-effective treatment option when compared to rFVIIa. This result is consistent with findings from a previous study in the same population of AHA with a high-titered inhibitor [25] . In addition to the robustness of the model across all tested ranges of Virtually, all ICERs over 5-day were above the cut-off of $684Á48/5 QALDs, $1368Á96/5 QALDs and $2053Á44/5 QALDs (which are equivalent to $50 000/QALY, $100 000/QALY and $150 000/QALY, respectively).
all input variables, a major strength of our model was that we utilized and integrated data from both the literature and our institution to input the parameters. Specifically, we used the costs from our own institution in the model, which reflected better estimates for the cost measurements than the usual reimbursement or Medicare allowance costs that were used in other studies. [25, 26] We further demonstrated the utility of using mathematical models [29-31] to approach a complex problem in the healthcare setting, and in today's healthcare environment, these models with economic outcomes will be increasingly important for treatment decisions and reimbursements, especially in a complex field such as Transfusion Medicine and Hemostasis/Thrombosis [32] [33] [34] [35] . Similar to other economic models in health care, our model has some limitations.
First, AHA is a very rare disease, only affecting 1Á3-1Á5 cases per million per year [2, 4, 5]. Thus, the estimates for several parameters may not be accurate. For example, the health utility index in this specific population has not been widely studied, and hence, in our model, we had to estimate the utility scores from a similar but not identical population [23, 24] . Therefore, we acknowledge the need for more utility elicitation studies in order to improve upon our model and future CEA studies involving AHA patients with high titre anti-factor VIII antibody (>5 BU). Nonetheless, the result of both the one-way sensitivity analysis and PSA over a wide range of possible values for the utility scores confirmed that they were insensitive variables, given that both the population receiving aPCC and the one receiving rFVIIa shared the same utilities. Fig. 2 One-way sensitivity analysis was performed to determine the robustness of each one variable on the model with regards to the incremental costeffectiveness ratios (ICER), which was represented on the x-axis. The wider the range of the ICER, the more impact the variable had on the cost-effectiveness of activated prothrombin complex concentrate (aPCC) vs. recombinant activated factor VII (rFVIIa). In all variables tested, either (1) aPCC was cheaper and more effective (i.e. higher QALD gained, ICER <0) compared to rFVIIa or (2) the ICER value was greater than $684Á46/5-day QALD (an equivalence of $50 000/QALY) which confirmed aPCC is a cost-effective treatment option compared to rFVIIa. Of note, all possible variations of the variables in Table 2 are tested, but only the variables that had a major impact on the ICER are shown. [Colour figure can be viewed at wileyonlinelibrary.com] Second, to simplify the approach, we modelled an ideal clinical scenario with several theoretical assumptions. For example, we assumed that if the patient developed thrombosis while receiving treatment, the aPCC or rFVIIa would be stopped and the patient would be moved to the ICU. Additionally, we did not account for the possibility of rebleeding after the initial bleeding stopped. Regarding mortality, we assumed that if death occurred, it happened at the beginning of the next day. In reality, these assumptions may not be completely true. However, the impact they had on the model was minimal, as they were embedded in both the aPCC and the rFVIIa options.
Third, although aPCC has undergone multiple steps of viral inactivation, there is a very small risk of transfusion-transmitted infection from this product, given that it is derived from pooled human plasma, while the risk of such transmission is virtually non-existent from rFVIIa, a recombinant product [11, 12] . However, given that the risk of transmission from aPCC is remote, even if accounted for, its impact on the model would be negligible due to the very significant difference in the costeffectiveness result between aPCC and rFVIIa obtained by the model.
Lastly, a CEA is designed to evaluate the costs and trade-offs, such as QALD gained in this model, of various treatment options from a global healthcare policy perspective. Using mathematical and statistical modelling techniques, the CEA assists in providing rational direction to achieve the goal of allocating limited resources to places where benefits can be maximized [17] . Fig. 3 Probabilistic sensitivity analysis -One thousand simulation samples were used to confirm the deterministic (base-case) analysis. The y-axis represents the incremental cost while the x-axis represents the incremental quality-adjusted life days (QALDs) gained. Virtually, all ICERs over 5-day were above the cut-off of $684Á48/5 QALDs, $1368Á96/5 QALDs and $2053Á44/5 QALDs (which are equivalent to $50 000/QALY, $100 000/QALY and $150 000/QALY, respectively). Nonetheless, the result of any CEA must be carefully interpreted when applied to patient care [33] . Specifically, since each patient may be different in terms of risks and responses to each treatment, a CEA result cannot be substituted for clinical judgement when providing care for the individual patient. In this case, although our models used parameters from different AHA patient cohorts and from our institutional data, the sensitivity analyses over a wide range of possibilities for each parameter confirmed the robustness of the model. This observation supports the generalizability of our conclusion that aPCC appeared to be a cost-effective treatment compared to rFVIIa in our study population. In reality, many hospitals may have only aPCC or rFVIIa (but not both) in their inventory. Given that AHA with bleeding has significant morbidity and mortality, there should not be any delay in initiating treatment with whatever option is available at that time.
In conclusion, in bleeding patients with AHA who have high titres of anti-factor VIII antibody (>5 BU), from a health economic perspective, aPCC appears to be a costeffective treatment option compared to rFVIIa after accounting for both advantages and disadvantages of each treatment. Therefore, if both aPCC and rFVIIa are available and there is no other contraindication clinically, aPCC should be considered in these patients to reduce healthcare-related costs to the society.
